Antibodies

Jump to navigation Jump to search

WikiDoc Resources for Antibodies

Articles

Most recent articles on Antibodies

Most cited articles on Antibodies

Review articles on Antibodies

Articles on Antibodies in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Antibodies

Images of Antibodies

Photos of Antibodies

Podcasts & MP3s on Antibodies

Videos on Antibodies

Evidence Based Medicine

Cochrane Collaboration on Antibodies

Bandolier on Antibodies

TRIP on Antibodies

Clinical Trials

Ongoing Trials on Antibodies at Clinical Trials.gov

Trial results on Antibodies

Clinical Trials on Antibodies at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Antibodies

NICE Guidance on Antibodies

NHS PRODIGY Guidance

FDA on Antibodies

CDC on Antibodies

Books

Books on Antibodies

News

Antibodies in the news

Be alerted to news on Antibodies

News trends on Antibodies

Commentary

Blogs on Antibodies

Definitions

Definitions of Antibodies

Patient Resources / Community

Patient resources on Antibodies

Discussion groups on Antibodies

Patient Handouts on Antibodies

Directions to Hospitals Treating Antibodies

Risk calculators and risk factors for Antibodies

Healthcare Provider Resources

Symptoms of Antibodies

Causes & Risk Factors for Antibodies

Diagnostic studies for Antibodies

Treatment of Antibodies

Continuing Medical Education (CME)

CME Programs on Antibodies

International

Antibodies en Espanol

Antibodies en Francais

Business

Antibodies in the Marketplace

Patents on Antibodies

Experimental / Informatics

List of terms related to Antibodies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview[edit]

Each antibody binds to a specific antigen; an interaction similar to a lock and key.

Antibodies are Y-shaped proteins that are found in blood or other bodily fluids of vertebrates, and are used by the immune system to identify and neutralize foreign objects, such as bacteria and viruses. They are made of a few basic structural units called chains; each antibody has two large heavy chains and two small light chains. There are several different types of antibody heavy chain, and several different kinds of antibodies, which are grouped into different isotypes based on which heavy chain they possess. Five different antibody isotypes are known in mammals, which perform different roles, and help direct the appropriate immune response for each different type of foreign object they encounter.<ref name=Market>Eleonora Market, F. Nina Papavasiliou (2003) V(D)J Recombination and the Evolution of the Adaptive Immune System PLoS Biology1(1): e16.</ref>

Although the general structure of all antibodies is very similar, a small region at the tip of the protein is extremely variable, allowing millions of antibodies with slightly different tip structures to exist. Each of these variants can bind to a different target, known as an antigen.<ref name=Janeway5>{{#invoke:citation/CS1|citation |CitationClass=book }}</ref> This huge diversity of antibodies allows the immune system to recognize an equally wide diversity of antigens. The unique part of the antigen recognized by an antibody is called an epitope. These epitopes fit precisely with their antibody, similar to a key fitting into a lock, in a highly specific interaction that allows antibodies to identify and bind only their unique antigen in the midst of the millions of different molecules that make up an organism. Recognition of an antigen by an antibody tags it for attack by other parts of the immune system. Antibodies can also neutralize targets directly by, for example, binding to a part of a pathogen that it needs to cause an infection.<ref name=Rhoades>{{#invoke:citation/CS1|citation |CitationClass=book }}</ref>

The large and diverse population of antibodies is generated by random combinations of a set of gene segments that encode different antigen binding sites (or paratopes), followed by random mutations in this area of the antibody gene, which create further diversity.<ref name=Market/><ref name=diaz>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> Antibody genes also re-organize in a process called class switching that changes the base of the heavy chain to another, creating a different isotype of the antibody that retains the antigen specific variable region. This allows a single antibody to be used by several different parts of the immune system.

Antibodies occur in two forms: a soluble form secreted into the blood and tissue fluids, and a membrane-bound form attached to the surface of a B cell that is called the B cell receptor (BCR). The BCR allows a B cell to detect when a specific antigen is present in the body and triggers B cell activation.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> Activated B cells differentiate into either antibody generating factories called plasma cells that secrete soluble antibody, or into memory cells that survive in the body for years afterwards to allow the immune system to remember an antigen and respond faster upon future exposures.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> Antibodies are, therefore, an essential component of the adaptive immune system that learns, adapts and remembers responses to invading pathogens. Production of antibodies is the main function of the humoral immune system.<ref name=Pier>{{#invoke:citation/CS1|citation |CitationClass=book }}</ref>

Isotypes[edit]

Antibody isotypes of mammals
Name Types Description Antibody Complexes
IgA 2 Found in mucosal areas, such as the gut, respiratory tract and urogenital tract, and prevents their colonization by pathogens.<ref>{{#invoke:Citation/CS1|citation CitationClass=journal

}}</ref> Also found in saliva, tears, and breast milk.|| rowspan="5" |Some antibodies form complexes that bind to multiple antigen molecules.

IgD 1 citation CitationClass=journal

}}</ref> Its function is less defined than other isotypes.

IgE 1 Binds to allergens and triggers histamine release from mast cells, and is involved in allergy. Also protects against parasitic worms.<ref name=Pier/>
IgG 4 In its four forms, provides the majority of antibody-based immunity against invading pathogens.<ref name=Pier/>
IgM 1 Expressed on the surface of B cells and in a secreted form with very high avidity. Eliminates pathogens in the early stages of B cell mediated immunity before there is sufficient IgG.<ref name=Pier/><ref name=Geisberger/>

Antibodies can come in different forms known as isotypes or classes. In mammals there are five antibody isotypes known as IgA, IgD, IgE,IgG and IgM. They are each named with an "Ig" prefix that stands for immunoglobulin, another name for antibody, and differ in their biological properties, functional locations and ability to deal with different antigens, as depicted in the table.<ref name = woof>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref>

The antibody isotype of a B cell changes during the cell's development and activation. Immature B cells, which have never been exposed to antigen, are known as naïve B cells and express only the IgM isotype in a cell surface bound form. B cells begin to express both IgM and IgD when they reach maturity - the co-expression of both these immunoglobulin isotypes renders the B cell 'mature' and ready to respond to antigen.<ref name=Goding>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> B cell activation follows engagement of the cell bound antibody molecule with an antigen, causing the cell to divide and differentiate into an antibody producing cell called a plasma cell. In this activated form, the B cell starts to produce antibody in a secreted form rather than a membrane-bound form. Some daughter cells of the activated B cells undergo isotype switching, a mechanism that causes the production of antiodies to change from IgM or IgD to the other antibody isotypes, IgE, IgA or IgG, that have defined roles in the immune system.

Structure[edit]

Antibodies are heavy globular plasma proteins that are also known as immunoglobulins. They have sugar chains added to some of their amino acid residues.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> In other words, antibodies are glycoproteins. The basic functional unit of each antibody is an immunoglobulin (Ig) monomer (containing only one Ig unit); secreted antibodies can also be dimeric with two Ig units as with IgA, tetrameric with four Ig units like teleost fish IgM, or pentameric with five Ig units, like mammalian IgM.<ref name = roux>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref>

Several immunoglobulin domains make up the two heavy chains (red and blue) and the two light chains (green and yellow) of an antibody. The immunoglobulin domains are composed of between 7 (IgC) and 9 (IgV) β-strands. See also:[http://www.emc.maricopa.edu/faculty/farabee/BIOBK/ANTIBODY.gif

Immunoglobulin domains[edit]

The Ig monomer is a "Y"-shaped molecule that consists of four polypeptide chains; two identical heavy chains and two identical light chains connected by disulfide bonds.<ref name = woof/> Each chain is composed of structural domains called Ig domains. These domains contain about 70-110 amino acids and are classified into different categories (for example, variable or IgV, and constant or IgC) according to their size and function.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> They possess a characteristic immunoglobulin fold in which two beta sheets create a “sandwich” shape, held together by interactions between conserved cysteines and other charged amino acids.

Heavy chain[edit]

{{#invoke:labelled list hatnote|labelledList|Further information}} There are five types of mammalian Ig heavy chain denoted by the Greek letters: α, δ, ε, γ, and μ.<ref name=Janeway5/> The type of heavy chain present defines the class of antibody; these chains are found in IgA, IgD, IgE, IgG, and IgM antibodies, respectively.<ref name=Rhoades/> Distinct heavy chains differ in size and composition; α and γ contain approximately 450 amino acids, while μ and ε have approximately 550 amino acids.<ref name=Janeway5/>

1. Fab region
2. Fc region
3. Heavy chain with one variable (VH) domain followed by a constant domain (CH1), a hinge region, and two more constant (CH2 and CH3) domains.
4. Light chain with one variable (VL) and one constant (CL) domain
5. Antigen binding site (paratope)
6. Hinge regions

Each heavy chain has two regions, the constant region and the variable region. The constant region is identical in all antibodies of the same isotype, but differs in antibodies of different isotypes. Heavy chains γ, α and δ have a constant region composed of three tandem (in a line) Ig domains, and a hinge region for added flexibility;<ref name = woof/> heavy chains μ and ε have a constant region composed of four immunoglobulin domains.<ref name=Janeway5/> The variable region of the heavy chain differs in antibodies produced by different B cells, but is the same for all antibodies produced by a single B cell or B cell clone. The variable region of each heavy chain is approximately 110 amino acids long and is composed of a single Ig domain.

Light chain[edit]

{{#invoke:labelled list hatnote|labelledList|Further information}} In mammals there are only two types of light chain, which are called lambda (λ) and kappa (κ).<ref name=Janeway5/> A light chain has two successive domains: one constant domain and one variable domain. The approximate length of a light chain is 211 to 217 amino acids.<ref name=Janeway5/> Each antibody contains two light chains that are always identical; only one type of light chain, κ or λ, is present per antibody in mammals. Other types of light chains, such as the iota (ι) chain, are found in lower vertebrates like Chondrichthyes and Teleostei.

Fab and Fc Regions[edit]

Some parts of an antibody have unique functions. The tip of the Y, for example, contains the site that binds antigen and, therefore, recognizes specific foreign objects. This region of the antibody is called the Fab (fragment, antigen binding) region. It is composed of one constant and one variable domain from each heavy and light chain of the antibody.<ref name= putnam79>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> The paratope is shaped at the amino terminal end of the antibody monomer by the variable domains from the heavy and light chains.

The base of the Y plays a role in modulating immune cell activity. This region is called the Fc (Fragment, crystallizable) region, and is composed of two heavy chains that contribute two or three constant domains depending on the class of the antibody.<ref name=Janeway5/> By binding to specific proteins the Fc region ensures that each antibody generates an appropriate immune response for a given antigen.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> The Fc region also binds to various cell receptors, such as Fc receptors, and other immune molecules, such as complement proteins. By doing this, it mediates different physiological effects including opsonization, cell lysis, and degranulation of mast cells, basophils and eosinophils.<ref name = woof/><ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref>

Function[edit]

{{#invoke:labelled list hatnote|labelledList|Further information}} Since antibodies exist freely in the bloodstream, they are said to be part of the humoral immune system. Circulating antibodies are produced by clonal B cells that specifically respond to only one antigen, a virus hull protein fragment, for example. Antibodies contribute to immunity in three main ways: they can prevent pathogens from entering or damaging cells by binding to them; they can stimulate removal of a pathogen by macrophages and other cells by coating the pathogen; and they can trigger direct pathogen destruction by stimulating other immune responses such as the complement pathway.<ref name=Ravetch>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref>


Activation of complement[edit]

Antibodies that bind to surface antigens on, for example a bacterium, attract the first component of the complement cascade with their Fc region and initiate activation of the "classical" complement system.<ref name=Ravetch/> This results in the killing of bacteria in two ways.<ref name=Pier/> First, the binding of the antibody and complement molecules marks the microbe for ingestion by phagocytes in a process called opsonization; these phagocytes are attracted by certain complement molecules generated in the complement cascade. Secondly, some complement system components form a membrane attack complex to assist antibodies to kill the bacterium directly.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref>

Activation of effector cells[edit]

To combat pathogens that replicate outside cells antibodies bind to pathogens to link them together, causing them to agglutinate. Since an antibody possesses at least two paratopes it can bind more than one antigen by binding identical epitopes carried on the surfaces of these antigens. By coating the pathogen, antibodies stimulate effector functions against the pathogen in cells that recognize their Fc region.<ref name=Pier/>

Those cells which recognize coated pathogens have Fc receptors which, as the name suggests, interacts with the Fc region of IgA, IgG, and IgE antibodies. The engagement of a particular antibody with the Fc receptor on a particular cell triggers an effector function of that cell; phagocytes will phagocytose, mast cells and neutrophils will degranulate, natural killer cells will release cytokines and cytotoxic molecules; that will ultimately result in destruction of the invading microbe. The Fc receptors are isotype-specific, which gives greater flexibility to the immune system, invoking only the appropriate immune mechanisms for distinct pathogens.<ref name=Janeway5/>

The secreted mammalian IgM has five Ig units. Each Ig unit (labeled 1) has two epitope binding Fab regions, so IgM is capable of binding up to 10 epitopes.


Immunoglobulin diversity[edit]

Virtually all microbes can trigger an antibody response. Successful recognition and eradication of many different types of microbes requires diversity among antibodies; their amino acid composition varies allowing them to interact with many different antigens.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> It has been estimated that humans generate about 10 billion different antibodies, each capable of binding a distinct epitope of an antigen.<ref name="pmid8612345">{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> Although a huge repertoire of different antibodies is generated in a single individual, the number of genes available to make these proteins is limited. Several complex genetic mechanisms have evolved that allow vertebrate B cells to generate a diverse pool of antibodies from a relatively small number of antibody genes.<ref name = namazee>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref>

Simplistic overview of V(D)J recombination of immunoglobulin heavy chains

V(D)J recombination[edit]

{{#invoke:labelled list hatnote|labelledList|Further information}}

Somatic recombination of immunoglobulins, also known as V(D)J recombination, involves the generation of a unique immunoglobulin variable region. The variable region of each immunoglobulin heavy or light chain is encoded in several pieces - known as gene segments. These segments are called variable (V), diversity (D) and joining (J) segments.<ref name = namazee/> V, D and J segments are found in Ig heavy chains, but only V and J segments are found in Ig light chains. Multiple copies of the V, D and J gene segments exist, and are tandemly arranged in the genomes of mammals. In the bone marrow, each developing B cell will assemble an immunoglobulin variable region by randomly selecting and combining one V, one D and one J gene segment (or one V and one J segment in the light chain). As there are multiple copies of each type of gene segment, and different combinations of gene segments can be used to generate each immunoglobulin variable region, this process generates a huge number of antibodies, each with different paratopes, and thus different antigen specificities.<ref name=Market/>

After a B cell produces a functional immunoglobulin gene during V(D)J recombination, it cannot express any other variable region (a process known as allelic exclusion) thus each B cell can produce antibodies containing only one kind of variable chain.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name=Janeway5/>

Somatic hypermutation and affinity maturation[edit]

For more details on this topic, see Somatic hypermutation and Affinity maturation

Another mechanism that generates antibody diversity occurs in the mature B cell. Following activation with antigen, B cells begin to proliferate rapidly. In these rapidly dividing cells, the genes encoding the variable domains of the heavy and light chains undergo a high rate of point mutation, by a process called somatic hypermutation (SHM). SHM results in approximately one nucleotide change per variable gene, per cell division.<ref name=diaz/> As a consequence, any daughter B cells will acquire slight amino acid differences in the variable domains of their antibody chains.

Somatic hypermutation serves to increase the diversity of the antibody pool and impacts the antibody’s antigen-binding affinity.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> Some point mutations will result in the production of antibodies that have a weaker interaction (low affinity) with their antigen than the original antibody, and some mutations will generate antibodies with a stronger interaction (high affinity).<ref name=orguil>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> B cells that express high affinity antibodies on their surface will receive a strong survival signal during interactions with other cells, whereas those with low affinity antibodies will not, and will die by apoptosis.<ref name=orguil/> Thus, B cells expressing higher affinity antibodies for will outcompete those with weaker affinities for function and survival. The process of generating antibodies with increased binding affinities is called affinity maturation. Affinity maturation occurs in mature B cells after V(D)J recombination, and is dependent on help from helper T cells.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref>

Mechanism of class switch recombination that allows isotype switching in activated B cells

Class switching[edit]

Isotype or class switching is a biological process occurring after activation of the B cell, which allows the cell to produce different classes of antibody (IgA, IgE, or IgG).<ref name=Market/> The different classes of antibody, and thus effector functions, are defined by the constant (C) regions of the immunoglobulin heavy chain. Initially, naïve B cells express only cell-surface IgM and IgD with identical antigen binding regions. Each isotype is adapted for a distinct function, therefore, after activation, an antibody with a IgG, IgA, or IgE effector function might be required to effectively eliminate an antigen. Class switching allows different daughter cells from the same activated B cell to produce antibodies of different isotypes. Only the constant region of the antibody heavy chain changes during class switching; the variable regions, and therefore antigen specificity, remain unchanged. Thus the progeny of a single B cell can produce antibodies, all specific for the same antigen, but with the ability to produce the effector function appropriate for each antigenic challenge. Class switching is triggered by cytokines; the isotype generated depends on which cytokines are present in the B cell environment.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref>

Class switching occurs in the heavy chain gene locus by a mechanism called class switch recombination (CSR). This mechanism relies on conserved nucleotide motifs, called switch (S) regions, found in DNA upstream of each constant region gene (except in the δ-chain). The DNA strand is broken by the activity of a series of enzymes at two selected S-regions.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> The variable domain exon is rejoined through a process called non-homologous end joining (NHEJ) to the desired constant region (γ, α or ε). This process results in an immunoglobulin gene that encodes an antibody of a different isotype.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref>

Medical applications[edit]

Disease diagnosis[edit]

Detection of particular antibodies is a very common form of medical diagnostics, and applications such as serology depend on these methods.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> For example, in biochemical assays for disease diagnosis,<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> a titer of antibodies directed against Epstein-Barr virus or Lyme disease is estimated from the blood. If those antibodies are not present, either the person is not infected, or the infection occurred a very long time ago, and the B cells generating these specific antibodies have naturally decayed. In clinical immunology, levels of individual classes of immunoglobulins are measured by nephelometry (or turbidimetry) to characterize the antibody profile of patient.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> Elevations in different classes of immunoglobulins are sometimes useful in determining the cause of liver damage in patients whom the diagnosis is unclear.<ref name=Rhoades/> For example, elevated IgA indicates alcoholic cirrhosis, elevated IgM indicates viral hepatitis and primary biliary cirrhosis, while IgG is elevated in viral hepatitis, autoimmune hepatitis and cirrhosis. Autoimmune disorders can often be traced to antibodies that bind the body's own epitopes; many can be detected through blood tests. Antibodies directed against red blood cell surface antigens in immune mediated hemolytic anemia are detected with the Coombs test.<ref name=Dean>{{#invoke:citation/CS1|citation |CitationClass=book }}</ref> The Coombs test is also used for antibody screening in blood transfusion preparation and also for antibody screening in antenatal women.<ref name=Dean/> Practically, several immunodiagnostic methods based on detection of complex antigen-antibody are used to diagnose infectious diseases, for example ELISA, immunofluorescence, Western blot, immunodiffusion, and immunoelectrophoresis.

Disease therapy[edit]

"Targeted" monoclonal antibody therapy is employed to treat diseases such as rheumatoid arthritis,<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> multiple sclerosis,<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> psoriasis,<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> and many forms of cancer including non-Hodgkin's lymphoma,<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> colorectal cancer, head and neck cancer and breast cancer.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> Some immune deficiencies, such as X-linked agammaglobulinemia and hypogammaglobulinemia, result in partial or complete lack of antibodies.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> These diseases are often treated by inducing a short term form of immunity called passive immunity. Passive immunity is achieved through the transfer of ready-made antibodies in the form of human or animal serum, pooled immunoglobulin or monoclonal antibodies, into the affected individual.<ref name=USC>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Prenatal therapy[edit]

{{#invoke:labelled list hatnote|labelledList|Further information}} Rho(D) Immune Globulin antibodies are specific for human Rhesus D antigen, also known as Rhesus factor.<ref name= Fung>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> These antibodies are known under several brand names, including RhoGAM. Rhesus factor is an antigen found on red blood cells; individuals that are Rhesus-positive (Rh+) have this antigen on their red blood cells and individuals that are Rhesus-negative (Rh-) do not. During normal childbirth, delivery trauma or complications during pregnancy, blood from a fetus can enter the mother's system. In the case of an Rh-incompatible mother and child, consequential blood mixing may sensitize an Rh- mother to the Rh antigen on the blood cells of the Rh+ child, putting the remainder of the pregnancy, and any subsequent pregnancies, at risk for hemolytic disease of the newborn.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> RhoGAM is administered as part of a prenatal treatment regimen to prevent sensitization that may occur when a Rhesus-negative mother has a Rhesus-positive fetus. Treatment of a mother with RhoGAM antibodies prior to and immediately after trauma and delivery destroys Rh antigen in the mother's system from the fetus. Importantly, this occurs before the antigen can stimulate maternal B cells to "remember" Rh antigen by generating memory B cells. Therefore, her humoral immune system will not make anti-Rh antibodies, and will not attack the Rhesus antigens of the current or subsequent baby. RhoGAM treatment prevents sensitization that can lead to Rh disease, but does not prevent or treat the underlying disease itself.<ref name= Fung/>

Research applications[edit]

Immunofluorescence image of the eukaryotic cytoskeleton. Actin filaments are shown in red, microtubules in green, and the nuclei in blue.

Specific antibodies are produced by injecting an antigen into a mammal, such as a mouse, rat or rabbit for small quantities of antibody, or goat, sheep, or horse for large quantities of antibody. Blood isolated from these animals contains polyclonal antibodies — multiple antibodies that bind to the same antigen — in the serum, which can now be called antiserum. Antigens are also injected into chickens for generation of polyclonal antibodies in egg yolk.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> To obtain antibody that is specific for a single epitope of an antigen, antibody-secreting lymphocytes are isolated from the animal and immortalized by fusing them with a cancer cell line. The fused cells are called hybridomas, and will continually grow and secrete antibody in culture. Single hybridoma cells are isolated by dilution cloning to generate cell clones that all produce the same antibody; these antibodies are called monoclonal antibodies.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> Generated polyclonal and monoclonal antibodies are often purified using Protein A/G or antigen-affinity chromatography.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref>

Use[edit]

In research, purified antibodies are used in many applications. They are most commonly used to identify and locate intracellular and extracellular proteins. Antibodies are used in flow cytometry to differentiate cell types by the proteins they express; different types of cell express different combinations of cluster of differentiation molecules on their surface, and produce different intracellular and secretable proteins.<ref name=Stecher>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> They are also used in immunoprecipitation to separate proteins and anything bound to them (co-immunoprecipitation) from other molecules in a cell lysate,<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> in Western blot analyses to identify proteins separated by electrophoresis,<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> and in immunohistochemistry or immunofluorescence to examine protein expression in tissue sections or to locate proteins within cells with the assistance of a microscope.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref name=Stecher/> Proteins can also be detected and quantified with antibodies, using ELISA and ELISPOT techniques.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref><ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref>

History[edit]

{{#invoke:Labelled list hatnote|labelledList|See also}} The study of antibodies began in 1890 when Emil von Behring and Shibasaburo Kitasato described antibody activity against diphtheria and tetanus toxins. Behring and Kitasato put forward the theory of humoral immunity, proposing that a mediator in serum could react with a foreign antigen.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> Their idea prompted Paul Ehrlich to propose the side chain theory for antibody and antigen interaction in 1897, when he hypothesized that receptors (described as “side chains”) on the surface of cells could bind specifically to toxins – in a "lock-and-key" interaction – and that this binding reaction was the trigger for the production of antibodies.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> Other researchers believed that antibodies existed freely in the blood and, in 1904, Almroth Wright suggested that soluble antibodies coated bacteria to label them for phagocytosis and killing; a process that he named opsoninization.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref>

In the 1920s, Michael Heidelberger and Oswald Avery observed that antigens could be precipitated by antibodies and went on to show that antibodies were made of protein.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> The biochemical properties of antigen-antibody binding interactions were examined in more detail in the late 1930s by John Marrack.<ref>{{#invoke:citation/CS1|citation |CitationClass=book }}</ref> The next major advance was in the 1940s, when Linus Pauling confirmed the lock-and-key theory proposed by Ehrlich by showing that the interactions between antibodies and antigens depended more on their shape than their chemical composition.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> In 1948, Astrid Fagreaus discovered that B cells, in the form of plasma cells, were responsible for generating antibodies.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref>

Further work concentrated on characterizing the structures of the antibody proteins. A major advance in these structural studies was the discovery in the early 1960s by Gerald Edelman and Joseph Gally of the antibody light chain,<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> and their realization that this protein was the same as the Bence-Jones protein described in 1845 by Henry Bence Jones.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> Edelman went on to discover that antibodies are composed of disulphide bond-linked heavy and light chains. Around the same time, antibody-binding (Fab) and antibody tail (Fc) regions of IgG were characterized by Rodney Porter.<ref name=edel>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> Together, these scientists deduced the structure and complete amino acid sequence of IgG, a feat for which they were jointly awarded the 1972 Nobel prize in Physiology or Medicine.<ref name=edel/> While most of these early studies focused on IgM and IgG, other immunoglobulin isotypes were identified in the 1960s: Thomas Tomasi discovered secretory antibody (IgA) <ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> and David Rowe and John Fahey identified IgD,<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> and IgE was identified by Kikishige Ishizaka and Teruki Ishizaka as a class of antibodies involved in allergic reactions.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref>

Genetic studies revealed the basis of the vast diversity of these antibody proteins when somatic recombination of immunoglobulin genes was identified by Susumu Tonegawa in 1976.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref>

See also[edit]

{{#invoke:Side box|main}}

References[edit]

<references group="" responsive="0"></references>

{{#invoke:Check for unknown parameters|check|unknown=|preview=Page using Template:Reflist with unknown parameter "_VALUE_"|ignoreblank=y| 1 | colwidth | group | liststyle | refs }}

External links[edit]

Acknowledgements[edit]

The content on this page was first contributed by: C. Michael Gibson, M.S., M.D.

Initial content for this page in some instances may have came from Wikipedia and AskDrWiki

Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources:

1.The Disease Database

2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3

3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7

List of contributors:

Suggested Reading and Key General References[edit]

Suggested Links and Web Resources[edit]

For Patients[edit]


Template:Link FA ar:ضد (مناعة) bn:অ্যান্টিবডি bg:Антитяло ca:Anticòs cs:Protilátka da:Antistof (biologi) de:Antikörper fa:پادتن ko:항체 it:Anticorpo he:נוגדן lt:Antikūnas hu:Ellenanyag nl:Immunoglobuline no:Antistoff simple:Antibody sk:Protilátka sr:Антитело sh:Antitelo fi:Vasta-aine sv:Antikropp th:แอนติบอดี uk:Антитіло Template:Jb1 Template:WH Template:WS